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Despite resveratrol’s well-documented health benefits, its mechanism of action remains controver-
sial. In particular, the direct molecular target of resveratrol has been elusive. Park et al. now show
that resveratrol directly inhibits cAMP-dependent phosphodiesterases, triggering a cascade of
events that converge on the important energy-sensing metabolic regulators AMPK, SIRT1, and
PGC-1a.For nearly 75 years, calorie restriction
(CR) has been the most consistent behav-
ioral intervention capable of extending life
span and protecting against age-associ-
ated metabolic disease. Since the report
that resveratrol—a polyphenol found in
the skin of grapes—mimics the life-span-
extending effects of CR in budding yeast
(Howitz et al., 2003), this compound has
been studied intensely. Debate about
the direct targets, downstream effectors,
and molecular mechanism by which res-
veratrol improves health span has en-
sued. In this issue, Park et al. (2012) iden-
tify phosphodiesterase (PDE) enzymes as
direct targets of resveratrol and propose
that resveratrol indirectly activates the
sirtuin SIRT1 through a signaling cascade
involving cAMP, Epac1, and AMPK.
Resveratrol burst into the news nearly
20 years ago, when it was proposed to
account for the unique effects of red wine
on life span and health. Subsequently, re-
sveratrol was linked to myriad physiolog-
ical benefits, including protection against
cardiovascular disease, cancer, age-
related deterioration, and the pathological
consequences of high-fat diets (Baur,
2010). Resveratrol was reported to exert
its effects by directly activating the yeast
Sir2 protein and its mammalian homolog
SIRT1 (Howitz et al., 2003). These mem-
bers of the sirtuin family catalyze NAD+-
dependent deacetylation reactions. The
resveratrol-sirtuin connection sparked a
torrent of excitement, in part because
sirtuins had been independently linked to
life span regulation in budding yeast (Kae-
berlein et al., 1999).
Over the last decade, fundamental
roles for mammalian sirtuins in numerouscellular processes that impact metabo-
lism, genomic stability, and aging-related
disease have been demonstrated (Naka-
gawa and Guarente, 2011). Among these
functions, SIRT1 deacetylates and acti-
vates PGC-1a, a master transcriptional
regulator of genes involved in energy con-
trol, ultimately leading to improved mito-
chondrial function and protection against
metabolic disease (Lagouge et al., 2006).
Thus, the notion that resveratrol acts
as a CR mimetic by activating sirtuins
seemed promising.
However, the observed activation of
SIRT1 by resveratrol in vitro now appears
to be an artifact of the assay used, casting
doubt on the direct resveratrol-SIRT1
connection (Baur, 2010). This raises two
important questions: How does resvera-
trol lead to SIRT1 activation in vivo, and
what is the direct cellular target of res-
veratrol? A series of studies provided
some initial answers by showing that res-
veratrol can activate SIRT1 indirectly
through AMPK, another energy-sensing
enzyme that is required for many of the
adaptations triggered by CR (Canto´
et al., 2010; Um et al., 2010). AMPK
promotes the activation of PGC-1a by
SIRT1 through several mechanisms,
including a priming phosphorylation that
is required for its deacetylation by SIRT1
and an increase in NAD+ concentration,
which is rate limiting for SIRT1 activity
(Canto´ and Auwerx, 2010).
Until now, AMPK activation was the
most upstream signaling event known
to be triggered by resveratrol, but like
SIRT1, AMPKdid not appear to be a direct
resveratrol target. Now, Park and col-
leagues (Park et al., 2012) seem to haveCell 148found the missing link between resvera-
trol and AMPK. The authors provide evi-
dence that resveratrol directly inhibits
several PDE enzymes, and they systemat-
ically delineate the steps that lead from
PDE inhibition to AMPK activation (Fig-
ure 1). These steps include increased
levels of the ubiquitous second mes-
senger cAMP, activation of the cAMP-
dependent guanine nucleotide exchange
factor Epac1, and increased intracel-
lular calcium to activate CamKKb, which
phosphorylates and activates AMPK.
Importantly, the PDE4 inhibitor rolipram
phenocopies the cellular signaling events
induced by resveratrol, including in-
creased cAMP levels, Epac1-dependent
activation of AMPK, increased NAD+,
and increased deacetylation of PGC-1a.
Park et al. complement this compre-
hensive pathway dissection with compel-
ling in vivo experiments in mice. When fed
to mice on a high-fat diet, rolipram in-
duced a gene expression pattern that
mirrors that induced by resveratrol in
multiple mouse tissues. And like resvera-
trol-treated mice, rolipram-treated mice
showed improved mitochondrial func-
tion, increased physical endurance, in-
creased basal metabolism, and protec-
tion against diet-induced obesity and
glucose intolerance.
Together, these data paint a detailed
picture of how resveratrol activates
AMPK and SIRT1 to produce metabolic
benefits, with some interesting mecha-
nistic and clinical implications. Resvera-
trol is thought to produce its health
benefits by mimicking CR. Does CR pro-
duce beneficial health effects by acti-
vating the same signaling cascade as, February 3, 2012 ª2012 Elsevier Inc. 387
Figure 1. Dietary, Behavioral, and Pharmacologic Inputs Converge
on cAMP-AMPK-SIRT1 Signaling to Produce Metabolic Benefits
Resveratrol inhibits PDEs, leading to increased cAMP levels, Epac1 activation,
elevated intracellular calcium, and AMPK activation. Calorie restriction and
other behavioral inputs also activate AMPK. Downstream of AMPK, an
increase in NAD+ levels leads to SIRT1 activation, which promotes beneficial
metabolic changes primarily through deacetylation and activation of PGC-1a.
In a parallel pathway, increased cAMP levels activate PKA, which directly
phosphorylates and activates SIRT1. SIRT1 activation by either pathway, as
well as potential activation of other NAD+-dependent enzymes, can lead to
numerous physiologic outputs. Blue box (top) highlights findings reported by
Park et al. (2012); orange box (bottom) highlights pathway components
previously identified that reside downstream of those identified by Park et al.,
as well as some of the reported and theoretical outputs of the signaling
pathways detailed above. Blue arrows indicate the linear pathway proposed
by Park et al.; dashed lines indicate molecular connections previously re-
ported. PDE, phosphodiesterase; cAMP, cyclic AMP; Epac1, cAMP-regulated
guanine nucleotide exchange factor 1; CamKKb, calcium/calmodulin-depen-
dent kinase kinase beta; AMPK, AMP-activated protein kinase; PKA, protein
kinase A; NAD+, nicotinamide adenine dinucleotide; PGC-1a, peroxisome
proliferator-activated receptor gamma coactivator-1 alpha; ROS, reactive
oxygen species.resveratrol (cAMP-Epac1-
CamKKb-AMPK)? Can this
network of proteins be ex-
ploited to develop CR mim-
etics with higher specificity
and efficacy? A number of
sirtuin-activating compounds
(STACs) have been devel-
oped as promising thera-
peutic agents, and like resver-
atrol, these STACs appear to
influence SIRT1 activity indi-
rectly (Baur, 2010). Do any of
these molecules also function
by directly inhibiting PDEs?
Alternatively, by identifying
PDEs as direct resveratrol
targets, the authors’ findings
(Park et al., 2012) may open
the door to new uses for previ-
ously identified pharmaco-
logic agents. For example,
many of the players in the
resveratrol-responsive signal-
ing cascade also play anti-
inflammatory and neuropro-
tective roles (Nakagawa and
Guarente, 2011), and highly
selective PDE inhibitors are
currently being investigated
as treatments for a wide
range of pathologic con-
ditions including psychiatric
and neurodegenerative dis-
eases as well as inflammatory
disorders such as chronic ob-
structive pulmonary disease
(Houslay et al., 2005).
The complex narrative of
how resveratrol works also
provides exciting new dir-
ections for future research.
For example, how does
the cAMP-Epac1-CamKKb-
AMPK signaling cascade in-
tersect with other well-char-
acterized pathways inducedin different physiologic contexts such as
fasting, cold exposure, exercise, and
acute stress, all of which can lead to
a ‘‘fight-or-flight’’ b-adrenergic response?
These physiologic triggers activate many
of the same factors involved in the
response to resveratrol but involve differ-
ent inputs and connections, generating a
seemingly tangled web of interconnected
pathways. For example, b-adrenergic
activation of the cAMP/PKA cascade by388 Cell 148, February 3, 2012 ª2012 Elsevieacute stress results in the rapid phosphor-
ylation and activation of SIRT1 indepen-
dent of both AMPK and NAD+ concentra-
tion changes (Gerhart-Hines et al., 2011).
Occurring within minutes, this signaling
pathway allows increased fat utilization
and adaptive thermogenesis in response
to acute nutritional stress or cold expo-
sure. Although the study by Park et al.
(2012) focuses on the changes that occur
over hours to weeks, it seems plausibler Inc.that PDE inhibition by resver-
atrol might also be useful
in modulating physiologic
responses to acute stress.
Questions of output speci-
ficity do, however, remain.
For instance, given the nu-
merous roles for cAMP and
calcium in intracellular sig-
naling, which downstream
pathways are triggered by
resveratrol? With the in-
crease in NAD+, are other
NAD+-dependent enzymes—
such as the six other mam-




Finally, it will be interesting
to learn whether the Epac1-
AMPK-SIRT1 pathway oper-
ates in cell types besides
muscle and white adipose
tissue. For example, although
PDEs regulate cAMPsignaling
in cardiac myocytes, resvera-
trol does not appear to alter
PGC-1a acetylation or mito-
chondrial biogenesis in these
cells (Lagouge et al., 2006),
and inactivation of Pde4 in
mice results in heart defects
such as progressive cardio-
myopathy (Houslay et al.,
2005), suggesting that tissue-
varying responses might limit
the efficacy of pharmacologic
intervention. From molecular
details to in vivo characteriza-
tion, the biochemical circuit
described by Park et al.
(2012) provides important
insight into the mechanism
by which resveratrol pro-
motes metabolic health. But
in the intensely controversial,complex, and rapidly evolving field of
resveratrol and sirtuins, the identification
of PDEs as the putative ‘‘missing link’’ is
certainly not the end of the story.REFERENCES
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Tobin and colleagues show that both inhibition and excessive production of the inflammatorymedi-
ator TNFa impact the pathogenesis of tuberculosis (TB) and the response to therapy. Identifying a
critical role for the genetically determined balance between pro- and anti-inflammatory eicosanoids
in regulating TNFa levels provides a roadmap to tailored TB treatment based on host genotype.Mycobacterium tuberculosis (Mtb) has
been our unwelcome companion for
millennia, using humans to ‘‘walk’’ out of
Africa, ‘‘sail’’ out of Europe and ‘‘canoe’’
across North America. In order to infect
an estimated one-third of theworld’s pop-
ulation and cause 8.1 million new cases of
active TB annually (World Health Organi-
zation, 2011), Mtb must withstand and
exploit host immune responses to ensure
its survival and transmission. In turn, the
human immune response has been cali-
brated to optimize survival in the face of
this intracellular threat, as exemplified by
the immune control and absence of
pathology that characterize latent TB
infection. Infection develops into disease
due to bacterial dissemination resulting
from inadequate protective immunity,
whereas tissue pathology is caused by
an overly vigorous yet ineffective host
response. Identifying pathways that regu-
late and potentially dissociate protection
from pathology will aid rational develop-
ment of new interventions for treatmentand vaccination. In this issue of Cell,
Tobin and colleagues dissect a pivotal
genetic balance that maintains the host
between the two extremes of failed immu-
nity and damaging hyperimmunity (Tobin
et al., 2012).
The inhibition ofmacrophage apoptosis
and the concomitant induction of necrosis
is currently emerging as a pathway that is
important for Mtb virulence, allowing for
bacterial spread between cells prior to
the induction of an adaptive immune
response. In contrast, avirulent mycobac-
teria induce macrophage apoptosis, re-
sulting in prompt development of a
protective immune response. Converging
results from different labs have revealed
that the arachidonic acid metabolites,
eicosanoids, lipoxins, and leukotrienes
influence cell death patterns following
mycobacterial infection (Behr et al., 2010).
Lipoxin A4 (LXA4), produced through the
action of lipoxygenase enzyme, acts as
an anti-inflammatory mediator of myco-
bacterial-induced necrosis of infectedmacrophages; its key role is evidenced by
the greater resistance of LXA4-deficient
5-lipoxygense knockout (Alox5/) mice
to Mtb infection (Behar et al., 2011; Chen
et al., 2008; Divangahi et al., 2010).
Studying the natural host-pathogen
pair ofM. marinum in zebrafish, the Ram-
akrishnan laboratory previously reported
on the susceptibility to infection of mutant
fish lacking the Leukotriene A4 (LTA4)
hydrolase enzyme (Tobin et al., 2010),
responsible for converting LTA4 to proin-
flammatory Leukotriene B4 (LTB4). This
hypersusceptibility was due to increased
LXA4 levels, which resulted in decreased
transcription of TNFa and the promotion
of an anti-inflammatory environment.
Interestingly, humans heterozygous for
SNPs in the Leukotriene A4 hydrolase
(lta4h) gene were relatively protected
against tuberculosis in comparison to
either homozygote genotype. In the
current report, Tobin and colleagues
investigate the mechanisms underlying
heterozygote advantage in the eicosanoid, February 3, 2012 ª2012 Elsevier Inc. 389
